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Abstract
The recent increase in Bordetella pertussis incidence (whooping cough) presents a challenge
to global health. Recent studies have called into question the effectiveness of acellular B. per-
tussis vaccination in reducing transmission. Here we examine the epidemiological consequences
of an ineffective B. pertussis vaccine. Using a dynamic transmission model, we find that: 1) an
ineffective vaccine can account for the observed increase in B. pertussis incidence; 2) asymp-
tomatic infections can bias surveillance and upset situational awareness of B. pertussis; and
3) vaccinating individuals in close contact with infants too young to receive vaccine (so called
“cocooning” unvaccinated children) may be ineffective. Our results have important implications
for B. pertussis vaccination policy and paint a complicated picture for achieving herd immunity
and possible B. pertussis eradication.
Keywords: pertussis; whooping cough; vaccination policy; ineffective vaccination; asymp-
tomatic infection
Introduction
The worldwide incidence of Bordetella pertussis, an important causative agent of Whooping Cough,
has increased dramatically over the past 20 years and continues to climb [1]. Last year in the United
States alone, there were more diagnosed B. pertussis cases than in any year since 1955.1 This is
despite high vaccination coverage across developed countries [1, 2, 3]. Two general hypotheses
have been proposed to explain the rise in B. pertussis incidence: either vaccination coverage is
too low, where individuals remain unvaccinated, or unvaccinated susceptible individuals move into
populations; or, vaccinated individuals can still become infected [1, 4]. While vaccination coverage
has likely played a role in increasing incidence, coverage has historically been high (> 90% in many
populations) [1, 3]. This raises the likelihood that the rise in incidence is, at least in part, due to
low vaccine efficacy. The increasing B. pertussis incidence is temporally associated with a change in
the vaccine: in the mid-1990s, an acellular vaccine (aP) replaced the highly-effective, but side-effect
prone, whole-cell vaccine (wP) [2].
There are at least three reasons vaccinated individuals can become infected: one, the vaccine
failed to induce sterilizing immunity to the pathogen [5], two, the vaccine mounted a sterilizing
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immune response that waned over time [6], or three, the pathogen evolved to escape sterilizing
immunity induced by the vaccine [7]. A recent study by Warfel, Zimmerman, and Merkel [5] using
non-human primates as a model for pertussis infection, suggests that pertussis vaccine efficacy
may be more nuanced than previously thought. Their results suggest that individuals vaccinated
with current acellular pertussis vaccines (aP) can become asymptomatically infected, and can then
transmit infection to susceptible individuals.
Warfel et al. points out that asymptomatic infection of aP vaccinated individuals, and subse-
quent transmission, may partially account for the increase in observed pertussis incidence. However,
from a public health perspective, the presence of vaccinated individuals that can become asymp-
tomatically infected and can transmit disease has profound consequences beyond an increase in
incidence. In response to Warfel et al., Domenech de Celle`s et al. (2014) [8] concluded from a
qualitative comparison of age-specific infection rates in Sweden and a model of B. pertussis trans-
mission that aP must protect against transmission. The contrasting experimental and theoretical
results on transmission, in the context of potentially life-saving vaccination policy, highlights the
need for theoretical and empirical studies of human immunity from aP.
Using mathematical models of B. pertussis transmission we explore the effects of asymptomatic
transmission by vaccinated individuals on population-level transmission dynamics of pertussis, in-
cluding how it may render current vaccination policies ineffective. Our results suggest that: one,
the use of a non-transmission blocking, or low efficacy vaccine can account for the observed increase
in pertussis incidence, two a large asymptomatic infectious class can bias traditional surveillance
mechanisms for B. pertussis, and three, the necessary coverage level for herd-immunity may be
unattainable and the practice of “cocooning” unvaccinated children may be ineffective using only
the aP vaccine. The results on vaccination have important public health and clinical implications,
especially related to recommendations for isolating unvaccinated or partially-vaccinated infants.
The model
We formulate a Susceptible, Infected, Removed (SIR) model of pertussis transmission [9, 10, 11].
Briefly, susceptible individuals are born at rate µ, where they are vaccinated with whole-cell (wP)
or acellular (aP) pertussis vaccine, depending on which vaccine is currently in use. Our model
includes three vaccine epochs: one without vaccination, one with only wP vaccination, and one
with only aP. These epochs are non-overlapping, similar to the advent of wP and its eventual re-
placement by aP [2]. We assume those vaccinated with wP are completely immune to infection (see
discussion below). Those vaccinated with aP move into a vaccinated class where they can become
asymptomatically infected. Unvaccinated individuals become infected with pertussis at rate β and
become symptomatic with probability σ (sensitivity to which is explored in the Supplementary
Material), and aP vaccinated individuals become asymptomatically infected at rate β. We assume
no difference in transmissibility between symptomatic and asymptomatic individuals (see Supple-
mentary Material). Individuals recover from symptomatic and asymptomatic infection at rates γs
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Figure 1: Can an inefficient vaccine lead to increased transmission? Figure demonstrates
the percentage increase in observed symptomatic and unobserved asymptomatic infections after
transitioning from a wP to an aP vaccine, calculated by dividing the steady-state symptomatic
cases across varying aP coverage levels with no wP vaccination, to a scenario with 90% wP cov-
erage and no aP vaccination. Asymptomatic increases were calculated analogously. We see an
increase in symptomatic cases across a large range of aP vaccination coverage levels. See Sup-
plementary Information for model details. Parameters: birth rate (µ) = death rate (ν) = 1/75
years−1; recovery rates for symptomatic (γs) and asymptomatic (γa) = 14 days−1; probability
of symptomatic infection (σ) = 0.25; baseline wP vaccination rate = 0.9; transmissibility (β) is
calculated such that R0 = 18.
and γa. We assume that aP vaccine is perfectly effective, however this is a conservative assumption
with respect to our conclusions. The equations governing transmission dynamics, and analytical
expressions for the basic reproduction number and model equilibria are given in the Supplementary
Material.
Can changing to a non-transmission blocking vaccine lead to in-
creased observed pertussis transmission?
Figure 1 shows the percentage increase in observed symptomatic and unobserved asymptomatic
infections after transitioning from a wP to an aP vaccine. As aP vaccination coverage increases,
asymptomatic infections increase nearly 30-fold. We see a substantial increase in the observed
numbers of symptomatic cases as wP vaccination is replaced by aP vaccination. At low levels of
aP vaccination, there is a 5 to 15-fold increase in symptomatic cases. Only at extremely high levels
of aP vaccination (> 99%) is there no change in symptomatic infections.
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How does a non-transmission blocking vaccine affect situational
awareness?
From the global to the local-level, accurate knowledge of pertussis incidence (or “situational aware-
ness”) is an essential public health decision support tool, facilitating an assessment of transmission
risk, planning for surges in hospitalizations, and in making recommendations for protecting unvac-
cinated children. For example, how effective might the strategy of vaccinating individuals in close
contact with unprotected children (or “cocooning” [12, 13]) be if individuals vaccinated with aP
can still transmit disease? Additionally, the mere presence of asymptomatic infections renders an
inaccurate assessment of situational awareness through traditional surveillance mechanisms.
Figure 2 demonstrates the percent of the true infections observed at steady-state ([Observed
Incidence/Total Incidence-1]*100) as aP vaccination rate increases and the probability of symp-
tomatic infection (σ) increases. We find that for realistic aP coverage rates (between 85% and
95%), the percentage of total cases expected to be observed is low (< 15%), and are highly depen-
dent on the probability of an infection becoming symptomatic (a parameter that is generally not
known). These results are likely to be conservative given the low, but unknown, diagnosis rate of
asymptotic infections and known underreporting of symptomatic infections in adults [14].
Effects on herd immunity
A primary public health objective of vaccination is to achieve herd immunity without exposing
individuals to the morbidity and mortality associated with infection [15]. Herd immunity is achieved
when there is sufficient population-wide immunity to disrupt transmission. Attaining vaccination-
levels high enough for herd immunity (termed the critical vaccination threshold) is a first step
towards eradication. Thus from both an individual perspective and a public health perspective,
the level of vaccination needed for herd immunity is an important quantity.
Figure 3 illustrates the critical aP vaccination threshold. Importantly, this calculation takes
into account the coverage level of those individuals previously vaccinated with the transmission-
blocking wP vaccine. In ranges of R0 consistent with those observed for pertussis (16-20) [16], the
aP critical vaccination threshold is greater than 95%, even with perfect wP vaccination coverage.
Furthermore, with a modest R0 = 5 [17], the necessary aP vaccination coverage is greater than
80% (again with perfect wP vaccination coverage). These results have two implications: one, herd
immunity may be unattainable and “cocooning” ineffective with the current aP vaccine and two,
given the likelihood of waning immunity and less than perfect vaccine coverage, the window of
opportunity to achieve herd immunity, if it exists, is rapidly closing.
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Figure 2: How does an inefficient vaccine affect situational awareness? Figure shows
the percent difference in observed infections (symptomatic) from true infections (symptomatic +
asymptomatic) at steady-state as aP vaccination rate increases and the probability of symptomatic
infection increases. Shaded area indicates a range of reasonable aP vaccination rates. At current
aP vaccination coverage levels, the majority of cases are asymptomatic and therefore undetected.
See Supplementary Information for model details. Parameters: birth rate (µ) = death rate (ν) =
1/75 years−1; recovery rates for symptomatic (γs) and asymptomatic (γa) = 14 days−1; baseline
wP vaccination rate = 0.9; transmissibility (β) is calculated such that R0 = 18.
Discussion
An ineffective aP vaccine can account for the increase in pertussis incidence without waning im-
munity or evolution of pertussis away from protective immunity; complicates situational awareness
surrounding levels of current pertussis transmission; and makes achieving herd immunity difficult,
if not impossible. Importantly, if transmission occurs via asymptomatically infectious vaccinated
individuals (as suggested in Warfel et al. (2014)), the future of global B. pertussis control could be
in jeopardy.
As is the case with all models, the one used in this study makes a number of simplifying assump-
tions. However, most of these assumptions likely render our conclusions conservative. We assume
wP vaccination is 100% effective, which may not be the case [18]. However, this is analogous to
having lower coverage overall, and importantly implies that the coverage required for herd immu-
nity will be even higher. Our model does not explicitly account for waning immunity or evolution
of the pertussis bacterium [6, 19] – two factors which likely play a large role in the epidemiological
dynamics of B. pertussis. However, inclusion of one or both of these would merely increase the
number of individuals susceptible to both symptomatic and asymptomatic infection. Importantly,
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Figure 3: How does an inefficient vaccine affect herd immunity? Figure plots the critical aP
vaccination threshold required to achieve herd immunity taking into account previous wP vaccina-
tion levels (contours). Across a broad range of R0 values for B. pertussis, herd immunity can only
be achieved with high coverage rates of both wP and aP vaccination (blue region). Additionally, we
find that as wP vaccination levels increase, less aP coverage is necessary to achieve herd immunity
(red region). See Supplementary Information for model details. Parameters: birth rate (µ) = death
rate (ν) = 1/75 years−1; recovery rates for symptomatic (γs) and asymptomatic (γa) = 14 days−1;
probability of symptomatic infection (σ) = 0.25; transmissibility (β) is calculated per value of R0.
the qualitative results of this paper will only be exacerbated by waning vaccine immunity and/or
the evolution of vaccine resistance.
Our model also assumes that symptomatic and asymptomatic infections have the same basic
reproduction number. Although coughing may increase transmission, the total bacterial load in
the nasopharynx of B. pertussis-infected non-human primates is similar between symptomatic and
asymptomatic individuals [5]. The same study suggested that the duration of higher bacterial
loads may be longer in asymptomatic individuals. However, and perhaps more importantly, being
asymptomatic suggests individuals may not alter their behavior and thus contact more individuals
than a symptomatic individual. Therefore, it seems more plausible that the R0 for aP vaccinated
individuals is higher and thus have underestimated the critical vaccination threshold for achieving
herd immunity.
That there has been a rise in whooping cough incidence is irrefutable. The findings presented
in Warfel et al., in conjunction with ours, have profound implications for the understanding of B.
pertussis transmission dynamics and for vaccination policy. Specifically, our results may explain the
negative outcome found in a recent study of postnatal cocooning [12] and presents a complicated
picture for achieving herd immunity and possible eradication. Although we now have conflicting
6
theoretical [8], and experimental results [5] surrounding B. pertussis transmission, both have serious
caveats. The experimental work was done in a non-human primate system that may or may not be
a good approximation for human transmission dynamics, and the theoretical work did not present
a rigorous evaluation of the transmission hypothesis. Clearly more research is necessary, but if
our results hold, public health authorities may be facing a situation similar to that of polio and
OPV virus transmission [20]. Again suggesting a modification of recommendations to clinicians for
protecting unvaccinated children. In light of current evidence and our results, we cannot simply
dismiss the potential far-reaching epidemiological consequences of an ineffective B. pertussis vaccine.
Acknowledgements: The authors thank David Dowdy, Damien Caillaud, and Laurent He´bert-
Dufresne for helpful discussions. This work was supported by the Omidyar Foundation and the
Santa Fe Institute.
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Model Equations
We formulate a deterministic Susceptible, Infected, Removed (SIR) model of pertussis transmis-
sion [9, 10, 11]. Briefly, individuals are born susceptible to pertussis infection at rate µ, where
they are vaccinated with whole-cell (wP) or acellular (aP) pertussis vaccine at rates wP and aP ,
respectively. We assume those vaccinated with wP are completely immune to infection, while those
vaccinated with aP move into a vaccinated class where they are susceptible to asymptomatic in-
fection. Susceptible individuals become infected with pertussis at rate β and become symptomatic
at rate σ. Individuals recover from symptomatic and asymptomatic infection at rates γs and γa,
respectively. Individuals die at rate ν, which we set equal to µ to keep population size constant.
The equations governing transmission dynamics are:
S′(t) = µ · (1− wP − aP )− β[Is(t) + Ia(t)]S(t)− νS(t) (1)
I ′s(t) = βσ[Is(t) + Ia(t)]S(t)− γsIs(t)− νIs(t) (2)
I ′a(t) = β(1− σ)[Is(t) + Ia(t)]S(t) + β[Is(t) + Ia(t)]V (t)− γaIa(t)− νIa(t) (3)
V ′(t) = µ · aP − β[Is(t) + Ia(t)]V (t)− νV (t) (4)
R′(t) = µ · wP + γsIs(t) + γaIa(t)− νR(t) (5)
We begin simulations with neither wP or aP vaccination. After some time period, twP , we initiate
wP vaccination, and after that at taP , we stop wP vaccination and begin aP vaccination, similar
to replacement of wP by aP vaccines in the mid-1990s [2]. Although this model does not include
waning immunity, a process thought to be important for B. pertussis, we discuss below how this is
a conservative modeling choice with respect to our conclusions.
Steady-state Equilibria
Calculation of the stready-state equilibria of this model is done by equating Equations (1)–(5) to 0
and solving for the state variables, S, Is, Ia, V, and R. There are two equilibria. The disease-free
equilibrium is given by:
S∗ =
µ(1− aP − wP )
ν
(6)
I∗s = I
∗
a = 0 (7)
V ∗ =
aPµ
ν
(8)
R∗ =
µwP
ν
. (9)
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The other equilibrium has infectious and vaccination classes given by
I∗s = −
σρ
[
βµ
[
σρ(γa − γs) + ν(wP − 1) + γs(wP − 1)
]
+ ν(γa + ν)(γs + ν)
]
β(γs + ν)
[
σρ(γa − γs) + ν(wP − 1) + γs(wP − 1)
] (10)
I∗a =
(σρ− wP + 1)
[
βµ
[
σρ(γa − γs) + ν(wP − 1) + γs(wP − 1)
]
+ ν(γa + ν)(γs + ν)
]
β(γa + ν)
[
σρ(γa − γs) + ν(wP − 1) + γs(wP − 1)
] (11)
V ∗ = − aP (γa + ν)(γs + ν)
β
[
σρ(γa − γs) + ν(wP − 1) + γs(wP − 1)
] (12)
where ρ = (aP + wP − 1) for clarity.
Calculating R0
To calculate the basic reproduction number, R0, we follow the formulation as laid out in Diekmann
et al. [21]. R0 is the spectral radius of the Next Generation Matrix, K, (ie: R0 = ρ(K) = sup{|
λ |: λ ∈ σ(K)} where σ(·) denotes the spectrum of matrix K). We will decompose K into two
matrices: T, the transmission matrix, where Tij is the rate at which infected individuals in state
j infect individuals in state i; and Σ, the transition matrix, where Σij is the rate an individual in
state j transitions to state i. Diekmann et al. show that
K = −ETTΣ−1E (13)
Where T−1 is the inverse of matrix T and E is a matrix of unit column vectors eij for all i such
that the ith row of T is not identically zero.
We start by linearizing the system about the disease free equilibrium. Assuming ν = µ, Equa-
tions (6)-(9) become:
S∗ = (1− aP − wP ) (14)
I∗s = I
∗
a = 0 (15)
V ∗ = aP (16)
R∗ = wP. (17)
Using the model equations given above, we formulate the infection subsystem as:
I ′s = βσ[Is + Ia]S
∗ − γsIs − νIs
= βσ[Is + Ia](1− aP − wP )− γsIs − νIs (18)
I ′a = β(1− σ)[Is + Ia]S∗ + β[Is + Ia]V ∗ − γaIa − νIa
= β(1− σ)[Is + Ia](1− aP − wP ) + β[Is + Ia]aP − γaIa − νIa (19)
where the (t)s have been dropped for clarity.
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The rate of transmission into symptomatic and asymptomatic classes are given by
∂
∂Ia
(I ′s) = βσ(1− aP − wP ) (20)
∂
∂Is
(I ′a) = β(1− σ)(1− aP − wP ) (21)
∂
∂V
(I ′a) = βaP (22)
We find the transmission matrix to be:
T =
 βσ(1− aP − wP ) 0 00 β(1− σ)(1− aP − wP ) 0
0 βaP 0
 . (23)
Next we calculate the transition matrix, Σ, where the (i, j) entry is the rate at which an individ-
ual in state j transitions to state i (excluding infection transitions). Since there are no transitions
between infectious states in our infection subsystem, the transition matrix is a diagonal matrix
with the entries equal to the demographic and recovery rates of symptomatics, asymptomatics, and
aP vaccinated individuals:
Σ =
 −(ν + γs) 0 00 −(ν + γa) 0
0 0 µaP − ν
 . (24)
This makes finding the inverse of Σ trivial, it is simply the reciprocal of each non-zero entry. Now,
since none of the rows of T are identically zero, E is simply the 4-by-4 identity matrix and our
next generation matrix (NGM), is K = −ETTΣ−1E = −TΣ−1 =
−βσ(1−aP−wP )−(ν+γs) 0 0
0 −β(1−σ)(1−aP−wP )−(ν+γa) 0
0 − aPβ−(ν+γa) 0
 . (25)
The eigenvalues of K are{
0,
β(σ − 1)(aP + wP − 2)
γa + ν
, −βσ(aP + wP − 2)
γs + ν
}
. (26)
R0 is defined as the dominant eigenvalue of K, which is determined by the values of the param-
eters. The second eigenvalue corresponds to the R0 of the asymptomatic strain, and the third to
the R0 of the symptomatic strain. Thus, R0 for the entire system is given by the sum:
R0 =
β(σ − 1)(aP + wP − 1)
γa + ν
− βσ(aP + wP − 1)
γs + ν
(27)
=
(1− aP − wP )β(γs + ν + γaσ − γsσ)
(γa + ν)(γs + ν)
(28)
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Calculating the Herd Immunity Threshold
To achieve herd immunity, R0 for the system must be less than 1. Thus, if r0 is the basic repro-
ductive number for the system in absence of any vaccination, R0 = (2 − aP − wP ) · r0, and the
critical vaccination threshold for aP vaccine, aPc, is
R0 = (1− aP − wP )r0 < 1 (29)
=⇒ aPc < 1− 1/R0 − wP (30)
By symmetry, wPc < 1− 1/R0 − aP .
Note that in many scenarios, aPc > 1, and eradication is impossible by a single vaccination
alone.
Different Forces of Infection
Asymptomatic infection may be less transmissible than symptomatic infection due to less shedding
of bacteria through coughing. On the other hand, symptomatic individuals may have a smaller
force of infection due to self isolation. Thus, in the main text we assume equal forces of infection.
To assess sensitivity of our results to this assumption, we can formulate the model with unequal
forces of infection, βs and βa, for symptomatic and asymptotic infections, respectively. We modify
the infection term
β(1− σ)[Is(t) + Ia(t)]S(t)→ (1− σ)[βsIs(t) + βaIa(t)]S(t) (31)
The steady-state equilibrium becomes
I∗s = −
σ(aP+wP−2)(βaµ(γs+ν)(σ(aP+wP−2)−wP+2)−(γa+ν)(βsµσ(aP+wP−2)+ν2+γsν))
(γs+ν)(βa(γs+ν)(σ(aP+wP−2)−wP+2)−βsσ(aP+wP−2)(γa+ν)) (32)
I∗a =
(σ(aP+wP−2)−wP+2)(βaµ(γs+ν)(σ(aP+wP−2)−wP+2)−(γa+ν)(βsµσ(aP+wP−2)+ν2+γsν))
(γa+ν)(βa(γs+ν)(σ(aP+wP−2)−wP+2)−βsσ(aP+wP−2)(γa+ν)) (33)
V ∗ = aP (γa+ν)(γs+ν)βa(γs+ν)(σ(aP+wP−2)−wP+2)−βsσ(aP+wP−2)(γa+ν) . (34)
And R0,
R0 = (2− aP − wP )
(
βa(σ − 1)
(γa + ν)
− βsσ
(γs + ν)
)
. (35)
For a less transmissible asymptomatic infection, none of the results change qualitatively (Fig-
ure 4). As βa decreases relative to βs, R0 decreases modestly (Figure 5).
Sensitivity of Dynamics to Rate of Asymptomatic Infection (σ)
Figure 6 shows the lack of sensitivity of the dynamics to changes in asymptomatic infection rate
(σ).
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Figure 4: The effects of ineffective
B. pertussis vaccination under lower
asymptomatic transmission Figure is
analogous to the figures in the main text
with βa = βs/10. Other parameters: µ =
ν = 1/75 years−1; γs = γa = 14 days−1;
σ = 0.25; wP = aP = 0; R0 = 18.
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Figure 5: R0 changes as asymptomatic
infections become less transmissible
Figure shows R0 decreasing as asymptomatic
infections become less transmissible relative
to symptomatic infections (βs/βa). Param-
eters: µ = ν = 1/75 years−1; γs = γa = 14
days−1; σ = 0.25; wP = aP = 0.
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Figure 6: The effects of ineffective B. pertussis vaccination under higher asymptomatic
infection rate Figure is analogous to the figures in the main text with σ = 0.75. Other parameters:
µ = ν = 1/75 years−1; γs = γa = 14 days−1; σ = 0.25; wP = aP = 0; R0 = 18.
13
References
[1] D. W. Jackson and P. Rohani, “Perplexities of pertussis: recent global epidemiological trends and their
potential causes,” Epidemiology and Infection, pp. 1–13, Jan. 2013.
[2] K. M. Edwards, “Unraveling the challenges of pertussis,” Proceedings of the National Academy of
Sciences, vol. 111, no. 2, pp. 575–576, 2014.
[3] World Health Organization, “Progress towards global immunization goals - 2012,” Oct. 2013.
[4] R. A´guas, G. Gonc¸alves, and M. G. M. Gomes, “Pertussis: increasing disease as a consequence of
reducing transmission,” The Lancet infectious diseases, vol. 6, no. 2, pp. 112–117, 2006.
[5] J. M. Warfel, L. I. Zimmerman, and T. J. Merkel, “Acellular pertussis vaccines protect against disease
but fail to prevent infection and transmission in a nonhuman primate model,” Proceedings of the National
Academy of Sciences, vol. 111, no. 2, pp. 787–792, 2014.
[6] H. J. Wearing and P. Rohani, “Estimating the duration of pertussis immunity using epidemiological
signatures,” PLoS pathogens, vol. 5, no. 10, p. e1000647, 2009.
[7] F. R. Mooi, I. Van Loo, and A. J. King, “Adaptation of bordetella pertussis to vaccination: a cause for
its reemergence?,” Emerging infectious diseases, vol. 7, no. 3 Suppl, p. 526, 2001.
[8] M. Domenech de Celle`s, M. A. Riolo, F. M. G. Magpantay, P. Rohani, and A. A. King, “Epidemiological
evidence for herd immunity induced by acellular pertussis vaccines,” Proc Natl Acad Sci U S A, Feb
2014.
[9] H. W. Hethcote, “An age-structured model for pertussis transmission,” Mathematical biosciences,
vol. 145, no. 2, pp. 89–136, 1997.
[10] M. J. Keeling and P. Rohani, Modeling infectious diseases in humans and animals. Princeton: Princeton
University Press, 2008.
[11] R. M. Anderson, R. M. May, and B. Anderson, Infectious diseases of humans: dynamics and control,
vol. 28. Wiley Online Library, 1992.
[12] L. A. Castagnini, C. M. Healy, M. A. Rench, S. H. Wootton, F. M. Munoz, and C. J. Baker, “Impact
of maternal postpartum tetanus and diphtheria toxoids and acellular pertussis immunization on infant
pertussis infection,” Clinical infectious diseases, vol. 54, no. 1, pp. 78–84, 2012.
[13] C. M. Healy, M. A. Rench, and C. J. Baker, “Implementation of cocooning against pertussis in a
high-risk population,” Clinical Infectious Diseases, vol. 52, no. 2, pp. 157–162, 2011.
[14] P. Rendi-Wagner, J. Tobias, L. Moerman, S. Goren, R. Bassal, M. Green, and D. Cohen, “The seroepi-
demiology of bordetella pertussis in israel—estimate of incidence of infection,” Vaccine, vol. 28, no. 19,
pp. 3285 – 3290, 2010.
[15] P. Fine, K. Eames, and D. L. Heymann, ““herd immunity”: a rough guide,” Clinical infectious diseases,
vol. 52, no. 7, pp. 911–916, 2011.
[16] R. Anderson and R. May, “Immunisation and herd immunity,” Lancet, vol. 335, no. 8690, pp. 641–645,
1990.
[17] M. Kretzschmar, P. F. Teunis, and R. G. Pebody, “Incidence and reproduction numbers of pertussis:
estimates from serological and social contact data in five european countries,” PLoS medicine, vol. 7,
no. 6, p. e1000291, 2010.
[18] A. D. Bentsi-Enchill, S. A. Halperin, J. Scott, K. MacIsaac, and P. Duclos, “Estimates of the effectiveness
of a whole-cell pertussis vaccine from an outbreak in an immunized population,” Vaccine, vol. 15, no. 3,
pp. 301–306, 1997.
[19] A. M. Queenan, P. K. Cassiday, and A. Evangelista, “Pertactin-Negative Variants of Bordetella pertussis
in the United States,” New England Journal of Medicine, vol. 368, pp. 583–584, Feb. 2013.
14
[20] P. E. Fine and I. A. Carneiro, “Transmissibility and persistence of oral polio vaccine viruses: implications
for the global poliomyelitis eradication initiative,” American Journal of Epidemiology, vol. 150, no. 10,
pp. 1001–1021, 1999.
[21] O. Diekmann, J. A. P. Heesterbeek, and M. G. Roberts, “The construction of next-generation matrices
for compartmental epidemic models,” J R Soc Interface, Nov 2009.
15
